Genitourinary Cancers

Robert G. Uzzo, MD, discusses recent guidelines that have impacted clinical practice and ongoing biomarker research in the field of kidney cancer.

Sumanta Kumar Pal, MD, co-director of the Kidney Cancer Program at the City of Hope in Duarte, California, discusses the CheckMate-214 and CABOSUN trials for patients with renal cell carcinoma (RCC).

Matthew R. Zibelman, MD, discussed the promise of immunotherapy combinations for patients with kidney cancer.

Aly-Khan Lalani, MD, genitourinary oncology fellow, Dana-Farber Cancer Institute, discusses the results of a study investigating neutrophil-lymphocyte ratio (NLR) in patients with renal cell carcinoma (RCC).

Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the role of cabozantinib (Cabometyx) for patients with renal cell carcinoma

The therapeutic landscape is rapidly being altered by clinical trials of immunotherapy for patients with metastatic urothelial carcinoma, but simply changing the way quality of life is monitored could provide dramatic improvements in overall survival.

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the safety profile demonstrated with the combination of radium-223 and VEGF-targeted therapy for patients with renal cell carcinoma (RCC).

The aim of treating NMIBC is avoid the loss of the bladder and to prevent recurrence and progression to muscle-invasive disease.

Robert Jones, MD, discusses the future treatment landscape for patients with urothelial carcinoma in a more multidisciplinary setting.

Eva Comperat, MD, Hospital Tenon, discusses the treatment strategy for patients with neuroendocrine tumors (NETs).

John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.

Delivering IMRT to the bladder and pelvic nodes in patients with node-positive bladder cancer or high-risk node-negative bladder cancer is feasible with patients experiencing low toxicity and demonstrating low pelvic nodal rates of recurrence

A new procedure for monitoring RNA indicators of disease recurrence in urine samples from patients with a history of non-muscle invasive bladder cancer could spare these patients from undergoing multiple cystoscopies during routine follow-up.

Although immunotherapy shows great promise in meeting the need for effective treatment of muscle invasive bladder cancer, chemotherapy continues to be an important tool in treating patients with this disease and other forms of bladder and urothelial cancer.

Badrinath Konety, MD, MBA, department chair, Department of Urology, University of Minnesota, discusses the guidelines for the management of patients with bladder cancer.

Maria De Santis, MD, associate clinical professor at the University of Warwick, discusses the future treatment landscape for patients with bladder cancer.

Andrea Necchi, MD, discusses the current role of immunotherapy and chemotherapy for patients with muscle-invasive bladder cancer.

As first-line therapy in cisplatin-ineligible advanced urothelial cancer, pembrolizumab (Keytruda) was safe and provided tumor reduction as well as durable responses.

Michael R. Harrison, MD, discusses emerging data that are likely to impact the treatment landscape for patients with RCC.

Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.

Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses pressing unmet needs for patients with kidney cancer.